Noninvasive Detection of Occult yet Significant Liver Pathology in Alanine Aminotransferase–Normal Chronic Hepatitis B: A Multicenter Study
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf554 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Xinjie Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Alanine Transaminase, Liver. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovation Fund for Outstanding Doctoral Candidates of Peking University Health Science Center, Chinese Foundation for Hepatitis Prevention and Control.
Abstract (Originalsprache)
Background
Individuals with chronic hepatitis B (CHB) may harbor occult yet significant liver pathology despite normal alanine aminotransferase (ALT) levels, representing a major diagnostic challenge. We aimed to identify and validate noninvasive biomarkers for detecting significant liver pathology among this population.
Methods
This multicenter study screened 3258 CHB cases from 2013 to 2023, enrolling 137 treatment-naive hepatitis B e antigen (HBeAg)–positive (HBeAg+) and 253 HBeAg-negative patients with CHB with normal ALT levels (≤40 U/L). All participants underwent liver biopsy (reference standard) and measurement of liver function and novel biomarkers (including cytokeratin 18 [CK18]–M30, CK18-M65, Golgi protein (GP73), interleukin 10, and interleukin 2 receptor). Significant liver pathology was defined as inflammation grade and/or fibrosis stage ≥2. Sixteen CK18-M65–centered biomarker combinations were evaluated using 8 machine learning algorithms with multicenter stratified validation.
Results
Significant liver pathology was observed in 45.2% of patients with HBeAg+ infection. CK18-M65, CK18-M30, and GP73 were strongly correlated with the severity of pathology (correlation with inflammation grade, r = 0.757, r = 0.688, and r = 0.453, respectively; P < .001), independent of ALT levels. CK18-M65 demonstrated optimal diagnostic performance (area under the curve, 0.934 [95% confidence interval, .896–.973]) with 85.5% sensitivity and 88% specificity, especially in those with low-normal ALT. High CK18-M65 levels conferred >40-fold increased risk of severe liver injury (adjusted odds ratio, 40.64). The optimal biomarker combination (CK18-M65 + CK18-M30 + GP73) achieved an area under the receiver operating characteristic curve of 0.942, significantly outperforming liver stiffness measurement (0.824), aspartate aminotransferase–to-platelet ratio index (0.783), and Fibrosis-4 score (0.745) (all P < .01), with enhanced clinical utility. HBeAg-negative patients with CHB showed significant pathology in 46%, but exhibited weaker diagnostic performance.
Conclusions
CK18-M65–centered biomarker models suggest promising noninvasive tools for detecting occult liver pathology and risk stratification of ALT-normal HBeAg+ CHB infection, potentially avoiding unnecessary biopsies while identifying candidates for early intervention, nonetheless requiring validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University, Beijing, China.
- Department of Hepatology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong Province, China.
- Department of Liver Disease, Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, Xinjiang Province, China.
- Department of Laboratory Medicine, Infection Hospital Area of the First Affiliated Hospital of University of Science and Technology of China (Hefei Infectious Disease Hospital), Hefei, Anhui Province, China.
- Department of Laboratory Medicine, The People's Hospital of Chizhou, Chizhou, Anhui Province, China.
- Department of Infectious Diseases, The People's Hospital of Chizhou, Chizhou, Anhui Province, China.
ORCID-Profile: Tao Shen
Förderung
- National Natural Science Foundation of China
- Innovation Fund for Outstanding Doctoral Candidates of Peking University Health Science Center
- Chinese Foundation for Hepatitis Prevention and Control
Zitieren
APA
Li, X., Shi, M., Wang, X., Guo, F., Qi, Y., Wang, X., Lin, M., Liu, X., Kang, P., Zhang, Y., Ji, S., Hu, Y., Huang, J., Chi, X., & Shen, T. (2025). Noninvasive Detection of Occult yet Significant Liver Pathology in Alanine Aminotransferase–Normal Chronic Hepatitis B: A Multicenter Study. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf554
Vancouver
Li X, Shi M, Wang X, Guo F, Qi Y, Wang X, et al. Noninvasive Detection of Occult yet Significant Liver Pathology in Alanine Aminotransferase–Normal Chronic Hepatitis B: A Multicenter Study. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf554
BibTeX
@article{Li2025,
author = {Li, Xinjie and Shi, Meijie and Wang, Xiaozhong and Guo, Feng and Qi, Yingjie and Wang, Xihong and Lin, Ming and Liu, Xiaoling and Kang, Pengyuan and Zhang, Yuqi and Ji, Shanshan and Hu, Yizhong and Huang, Jinbao and Chi, Xiaoling and Shen, Tao},
title = {Noninvasive Detection of Occult yet Significant Liver Pathology in Alanine Aminotransferase–Normal Chronic Hepatitis B: A Multicenter Study},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf554}
}
EUVIMED